HER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD
|
|
- Heather Patterson
- 5 years ago
- Views:
Transcription
1 HER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD Carcinoma of the stomach is the fourth most common cancer and second most frequent cause of cancer-related mortality in the world. 1-8 Surgical intervention, including gastrectomy with lymphadenectomy, is currently the only potential curative therapy in localized disease. 3,5,6,8,9 However, gastric adenocarcinoma is often diagnosed in its late stage, and chemotherapeutic treatment modalities have unfortunately proven relatively ineffective, generally resulting in low survival rates, high recurrence rates, and overall poor prognoses. 1,2,5-8,10-13 Targeted molecular-based therapy capitalizing on genes and gene products harbored in gastric and gastroesophageal adenocarcinomas may provide an additional therapeutic method of intervention in advanced tumors. 5,6,11,14 The oncogene HER2/neu, located on chromosome 17q21, is a member of the Human Epidermal Growth Factor Receptor family, which regulates cellular functions, such as proliferation, differentiation, motility, migration, adhesion, and apoptosis, through a transmembrane protein kinase. 2-7,9,11,12,14 Oncogene amplification and subsequent increased protein expression is thought to mediate cell transformation in the initiation and progression of carcinogenesis and metastasis. 8 HER2/neu amplification occurs in approximately 10% to 30% of breast adenocarcinomas and correlates with a poor prognosis, including shorter survival rates and resistance to adjuvant chemotherapy and endocrine therapy. 4,6-9,11,13,15,16 HER2/neu testing has become the standard of care for invasive adenocarcinoma of the breast, because Herceptin (Trastuzumab), a recombinant humanized IgG1 monoclonal anti-her2 antibody, offers an effective treatment modality for HER2/neu positive tumors. 7,12,15,16 HER2/neu is also amplified in many other solid tumors, including those of the lung, head and neck, salivary gland, endometrium, uterine cervix, ovary, fallopian tube, prostate, urinary bladder, colon, and pancreas. 5-7,9,11,15 In upper gastrointestinal tract adenocarcinomas, the percentages of tumors with HER2/neu ampliflication vary widely, ranging from approximately 2% to 45% of gastroesophageal, 8.2% to 53.4% of gastric, and 11% to 73% of esophageal adenocarcinomas. 1,3,5-11,13-18 The 2009 ToGA (Trastuzumab for Gastric Cancer) trial reported that of locally advanced, recurrent, or metastatic tumors, approximately 33% of gastroesophageal junction and 22.1% of gastric adenocarcinomas were HER2 positive by either immunohistochemical (IHC) study or fluorescence in-situ hybridization (FISH) analysis. 1,4,8,9,12,16 The
2 ToGA trial further demonstrated high concordance rate of 87.2% between HER2/neu amplification conducted by FISH analysis and overexpression evaluated by IHC study. 1,6,8,11,16 The prognostic relevance of HER2/neu amplification and overexpression in gastric cancer is controversial, but some studies have shown an association with poor outcome, aggressive disease, and shorter survival. 3,5,6,8-12,15,16,18 Compared with standard chemotherapy treatment alone in the ToGA trial, the increased median overall survival with the addition of Trastuzumab in patients who were either IHC(3+) or FISH(+) was only a modest 2.7 months (11.1 months with chemotherapy alone compared to 13.8 months with the addition of Trastuzumab). 2,4,7-9,12,16,17 However, in patients who were IHC(3+) or [IHC(2+) and FISH(+)] (high protein expression) and received chemotherapy plus Trastuzumab, the median overall survival improved by 4.2 months (11.8 months with chemotherapy alone compared to 16 months with the addition of Trastuzumab). 1,2,7-9,11,16,17 Therefore, IHC should be utilized as the initial screening modality in HER2/neu testing, and cases equivocal/2+ for HER2 overexpression can be referred for FISH analysis. 1,4,8,9,16,17 The HER2/neu status assessment algorithm in gastroesophageal and gastric adenocarcinoma, which follows the inclusion criteria of the ToGA trial and was proposed by the European Medicines Agency, is depicted in Figure 1. Figure 1: Proposed algorithm for chemotherapy treatment with the addition of Trastuzumab eligibility in inoperable locally advanced or metastatic gastroesophageal and gastric adenocarcinoma 1,4,9 Test for HER2 protein over-expression by IHC (0) (1+) Equivocal (2+) Positive (3+) Test for HER2/neu gene amplification by FISH (HER2/CEP17 <2) Positive (HER2/CEP17 2) Eligible for Trastuzumab treatment
3 Studies have demonstrated intratumoral heterogeneity for both HER2 overexpression and HER2/neu amplification in gastroesophageal and gastric adenocarcinomas; and it is not clear how diverging heterogeneity occurs in tumor cells or how this phenomenon is relevant to targeted HER2 monoclonal antibody response. 1,9,10,12 Nonetheless, because intratumoral heterogeneity may result in false-negative results in endoscopic biopsies, multiple biopsies are desirable for HER2/neu status assessment, if feasible. 7,10,13,17 The ToGA trial showed that treatment of HER2/neu-positive advanced gastroesophageal and gastric adenocarcinoma with Trastuzumab, in addition to standard chemotherapy (capecitabine or flurouricil plus cisplatin), improved the response rate, median progression-free survival, and overall survival, providing evidence that these tumors are potential responders to monoclonal antibody-based therapy targeting the HER2 protein. 1,8 Trastuzamab was well tolerated when administered concomitantly with chemotherapeutic agents, and it is the first biological agent to show a survival benefit in advanced gastroesophageal and gastric adenocarcinoma. 2,4,7-9,11,12 The Food and Drug Administration (FDA) has approved Trastuzumab in combination with chemotherapy for metastatic gastric and gastroesophageal adenocarcinoma in patients without prior anticancer treatment. 1 Although, the ToGA trial included tumors that were inoperable, the role of Trastuzumab in the adjuvant setting may be promising. 4,7,12 Many researchers advocate assessment of HER2/neu status as a standard component of routine diagnostic work-up in advanced gastroesophageal and gastric adenocarcinoma to identify patients who would benefit from targeted monoclonal antibody therapy. 2-4,7,9,11,12,17 References 1. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18(1): doi: /PAP.0b013e d Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742): doi: /S (10)61121-X. 3. Xie SD, Xu CY, Shen JG, Jiang ZN, Wang LB. HER 2/neu protein expression in gastric cancer is associated with poor survival. Mol Med Rep. 2009;2(6): Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer. 2010;46(11): doi: /j.ejca Yan SY, Hu Y, Fan JG, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011;17(11): doi: /wjg.v17.i
4 6. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9): doi: /annonc/mdn Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int. 2010;2011: doi: /2011/ Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs. 2010;70(17): doi: / De Vita F, Giuliani F, Silverstris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev. 2010;36 Suppl 3:S11 5. doi: /S (10) Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 2010;32(1-2): doi: /CLO Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78(1): doi: / Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol. 2010;17(1): doi: /s Yan B, Yau, EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63(9): doi: /jcp Schoppmann SF, Jesch B, Friedrich J, et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010;34(12): doi: /PAS.0b013e3181f8be Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40(6): doi: /j.humpath Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010; 457(3): doi: /s Bouche O, Penault-Llorca F. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. Bull Cancer. 2010;97(12): doi: /bdc Thompson SK, Sullivan TR, Davies R, Ruszkiewicz AR. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol. 2011;18(7): doi: /s
5 Suggested Reading 1. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18(1): Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742): Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs. 2010;70(17): De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev Suppl 3:S Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010; 78(1): Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer. 2010;46(11): Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int. 2010;2011: Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer. 2010;46(11):
HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma
IJMCM Autumn 203, Vol 2, No 4 Original Article HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma Kourosh Movagharnejad, Majid Sharbatdaran,
More informationONCOLOGY LETTERS 5: , 2013
ONCOLOGY LETTERS 5: 559-563, 2013 The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel GIL BAR-SELA
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationIncidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma.
Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. Christophe Blay, Dan Cristian Chiforeanu, Eveline Boucher, Florian Cabillic, Romain Desgrippes, Bérengère Leconte,
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationExpression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer
MOLECULAR AND CLINICAL ONCOLOGY 2: 751-755 Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer RYOSUKE SHIBATA 1,
More informationResident Short Review. HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma
Resident Short Review HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma A Review of Histopathology, Diagnostic Testing, and Clinical Implications
More informationEditorial New guidelines for HER2 pathological diagnostics in gastric cancer
bs_bs_banner Pathology International 2016; 66: 57 62 doi:10.1111/pin.12390 Editorial New guidelines for HER2 pathological diagnostics in gastric cancer Ryo Wada, 1 Kenichi Hirabayashi, 2 Nobuyuki Ohike
More informationOriginal Article. Jennifer Jeung, MD; Roshan Patel, MD; Lizette Vila, MD; Dara Wakefield, MD; Chen Liu, MD, PhD
Original Article Quantitation of HER2/neu Expression in Primary Gastroesophageal Adenocarcinomas Using Conventional Light Microscopy and Quantitative Image Analysis Jennifer Jeung, MD; Roshan Patel, MD;
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationRESEARCH ARTICLE. Fatih Selcukbiricik 1 *, Sibel Erdamar 2, Evin Buyukunal 3, Suheyla Serrdengecti 3, Fuat Demirelli 3. Abstract.
DOI:http://dx.doi.org/10.731/APJCP.201.15.2.10607 RESEARCH ARTICLE Is Her-2 Status in the Primary Tumor Correlated with Matched Lymph Node Metastases in Patients with Gastric Cancer Undergoing Curative
More informationMinimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
THIEME Original article Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer Authors Institutions Irene Gullo 1, *, Federica Grillo 1, *, Luca Molinaro 2, Matteo Fassan
More informationTargeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example
Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Dennis J Slamon, MD, PhD Professor of Medicine Chief, Division of Hematology/Oncology; Director of Clinical/Translational
More informationHER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient
Journal of Pathology and Translational Medicine 2017; 51: 396-402 ORIGINAL ARTICLE HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient Dang Anh Thu Phan Vu Thien Nguyen Thi Ngoc
More informationCorrelation of Lauren s histological type and expression of E-cadherin and HER-2/ neu in gastric adenocarcinoma
IJPLM. 2016;2(1):OA2 ORIGINAL ARTICLES Correlation of Lauren s histological type and expression of E-cadherin and HER-2/ neu in gastric adenocarcinoma Khushboo Dewan 1*, Renu Madan 2, P Sengupta 3 1, 2,
More informationIt s not a four legged animal anymore. Disclosure
It s not a four legged animal anymore Parminder Singh, MD Assistant Professor of Medicine Division hematology and oncology No disclosures Disclosure 1 Four legged animal which use the tips of their toes,
More informationGastric Adenocarcinoma: Study of the Immunophenotypic Profile in View of the Latest Molecular Knowledge on Carcinogenesis
Human Journals Research Article March 2018 Vol.:11, Issue:4 All rights are reserved by Stefania Erra et al. Gastric Adenocarcinoma: Study of the Immunophenotypic Profile in View of the Latest Molecular
More informationRESEARCH ARTICLE. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India
DOI:10.22034/APJCP.2018.19.5.1381 RESEARCH ARTICLE Editorial Process: Submission:01/27/2018 Acceptance:03/29/2018 Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationClinical Policy: Her2/neu Testing Reference Number: CP.MP.155
Clinical Policy: Her2/neu Testing Reference Number: CP.MP.155 Effective Date: June 2004 Last Review Date: June 2017 Coding Implications Revision Log See Important Reminder at the end of this policy for
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationMT09 - Normal Human Tissue Microarray, FDA
Reveal Biosciences offers Histochemical Staining, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Whole Slide Imaging, and Quantitative Image Analysis on any TMA MT09 - Normal Human Tissue Microarray,
More informationHER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
ONCOLOGY LETTERS 6: 13-18, 2013 HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma JUN XING HUANG 1, KUN ZHAO 1, MEI LIN
More informationDiscordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma
Original Article Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma Ellie Chan 1, Lizette Vila Duckworth 2, Ahmad Alkhasawneh 2, Tania Zuluaga Toro
More informationBreast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg
More informationCorporate Medical Policy
Corporate Medical Policy Pertuzumab for Treatment of Malignancies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pertuzumab_for_treatment_of_malignancies 2/2013 4/2017 4/2018 6/2017
More informationKey words: gastric cancer, tumor location, pathology, outcome
JBUON 2019; 24(2): 650-655 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Addition of taxanes to combination chemotherapy in distal intestinal
More informationReviews in Clinical Medicine
Mashhad University of Medical Sciences (MUMS) Reviews in Clinical Medicine Clinical Research Development Center Ghaem Hospital Prognostic value of HER2/neu expression in patients with prostate cancer:
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationContinuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience
Original Article Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience Humaid O. Al-Shamsi 1, Yazan Fahmawi 1, Ibrahim Dahbour 1,
More informationOriginal article. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous
Original article A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein over-expression and gene-amplification reveal intratumoral heterogeneity
More informationReview Article HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
SAGE-Hindawi Access to Research Pathology Research International Volume 2011, Article ID 674182, 10 pages doi:10.4061/2011/674182 Review Article HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
More informationc-erbb-2 expression and prognosis of gastric cancer: a meta-analysis
c-erbb-2 expression and prognosis of gastric cancer: a meta-analysis Z.Q. Wang and B.J. Sun Department of Surgery, Affiliated Tongren Hospital, Shanghai Jiaotong University, Shanghai, China Corresponding
More informationMET-Amplified Intramucosal Gastric Cancer Widely Metastatic after Complete Endoscopic Submucosal Dissection
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2014 Aug 25 [Epub ahead of print] Case Report http://dx.doi.org/10.4143/crt.2013.137 Open Access MET-Amplified Intramucosal Gastric Cancer Widely Metastatic
More informationTrastuzumab for the treatment of HER2 positive advanced gastric cancer Appraisal Consultation Document (ACD)
Trastuzumab for the treatment of HER2 positive advanced gastric cancer Appraisal Consultation Document (ACD) Comments submitted by Dr Patrick Cadigan, RCP registrar on behalf of: NCRI/RCP/RCR/ACP/JCCO
More informationSystematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience
Woo et al. Diagnostic Pathology (2016) 11:102 DOI 10.1186/s13000-016-0553-8 RESEARCH Open Access Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience Jennifer S. Woo
More informationIdeal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
/, Vol. 6, No. 35 Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens Sangjeong Ahn 1,6,*, Soomin Ahn 1,2,*, Michael Van Vrancken 1,*, Minju Lee 1,
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationAssociation (2013), 16(1): の論文は出版社版でありません 引用の際には出版社版をご確認ご利用ください This is not the publish
Title HER2 expression and its clinicopath resectable gastric cancer. Kataoka, Yoshiki; Okabe, Hiroshi; Y Author(s) Minamiguchi, Sachiko; Yoshimura, Ke Sakai, Yoshiharu Gastric cancer : official journal
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationSeite 1 von 5 A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: BO18255 Previous Study Return
More informationKristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD
AJCP / Original Article Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
More informationAuthor s response to reviews
Author s response to reviews Title: Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections Authors: Renato Santos Laboissiere
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationHER2/neu testing for anti-her2-based therapies in patients with unresectable and/or metastatic gastric cancer
JCP Online First, published on May 8, 2012 as 10.1136/jclinpath-2012-200774 Original article 1 Gastrointestinal Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain 2 Medical
More informationWelcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016
HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationDEPARTMENT OF ONCOLOGY ELECTIVE
DEPARTMENT OF ONCOLOGY ELECTIVE 2015-2016 www.uwo.ca/oncology Oncology Elective Program Administrator: Ms. Kimberly Trudgeon Room A4-901C (Admin) LHSC London Regional Cancer Centre (Victoria Campus) Phone:
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #450 (NQF 1858): Trastuzumab Received By Patients With AJCC Stage I (T1c) III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy National Quality Strategy Domain: Effective Clinical
More informationHER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value conclusions from 924 cases of two independent series
Cellular Oncology 32 (2010) 57 65 57 DOI 10.3233/CLO-2009-0497 IOS Press HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value conclusions from 924 cases of two independent
More informationTechnology appraisal guidance Published: 24 November 2010 nice.org.uk/guidance/ta208
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer Technology appraisal guidance Published: 24 November 2010 nice.org.uk/guidance/ta208 NICE 2018. All rights reserved. Subject to
More informationNEUROENDOCRINE DIFFERENTIATION IN EPITHELIAL TUMORS Marco Volante
NEUROENDOCRINE DIFFERENTIATION IN EPITHELIAL TUMORS Marco Volante University of Turin, San Luigi Hospital, Orbassano, Turin, Italy marco.volante@unito.it pure NE tum..a grey zone pure non-ne ca. 0% NE
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationExosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study
GBCC 2017: ABS-0017 Exosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study Soo Jung Lee 1, Jeeyeon Lee 2, Jin Hyang Jung 2, Ho Yong Park 2, Chan Hyeong Lee 3, Pyong
More informationB Breast cancer, managing risk of lobular, in hereditary diffuse gastric cancer, 51
Index Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, gastric. See also Gastric cancer. D2 nodal dissection for 57 70 Adjuvant therapy, for gastric cancer, impact of D2 dissection
More informationSumida T, Hamakawa H. Telomerase and oral cancer. Oral Oncol. 37(4): ,
Sogawa K, Yamada T, Sumida T, Hamakawa H, Oda H, Tashiro S, Matsuda M, Matsumoto K, Okutani K Induction of K-562 cell apoptosis and inhibitory effect of DNA topoisomerase-i by a marine microalgae G3 polysaccharide.
More informationMonitoring Metastatic Breast Cancer with Serum HER-2/neu: Individual Patient Profiles
Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the
More informationHerceptin, Perjeta and Kadcyla AHM
Herceptin, Perjeta and Kadcyla AHM Clinical Indications Herceptin (trastuzumab) is considered medically necessary for use with 1 or more of the following with over-express the HER2 (human epidermal growth
More informationNational Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)
National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: 13-14 (V2) Produced as part of the Cancer Research UK - Public Health
More informationUSCAP 2012: Companion Meeting of the AAOOP. Update on lacrimal gland neoplasms: Molecular pathology of interest
USCAP 2012: Companion Meeting of the AAOOP Vancouver BC, Canada, March 17, 2012 Update on lacrimal gland neoplasms: Molecular pathology of interest Valerie A. White MD, MHSc, FRCPC Department of Pathology
More informationStage 4 gastric adenocarcinoma icd 10
> Stage 4 gastric adenocarcinoma icd 10 stage iii; Carcinoma of colon, stage iv; Colon cancer metastatic to unspecified site; Hereditary nonpolyposis colon cancer; Malignant tumor of colon; Metastasis.
More informationWhat is HER2 positive breast cancer in 2018? Updated ASCO-CAP guidelines. Giuseppe Viale University of Milan European Institute of Oncology
What is HER2 positive breast cancer in 2018? Updated ASCO-CAP guidelines Giuseppe Viale University of Milan European Institute of Oncology Mission accomplished! First alarming results Breast Intergroup
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #449 (NQF 1857): HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies National Quality Strategy Domain: Efficiency and Cost Reduction 2017 OPTIONS
More informationEvaluation of pharmacological therapies used in Costa Rica in patients with metastatic gastric cancer: a retrospective study
Original Article Evaluation of pharmacological therapies used in Costa Rica in patients with metastatic gastric cancer: a retrospective study Eugenia Cordero-García 1,2, Allan Ramos-Esquivel 3,4, Warner
More informationVersion 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-
Introduction: These guidelines represent systematically developed statements to assist in the provision of quality assured HER2 testing in breast and gastric/ gastro-oesophageal carcinoma. They are based
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationPrognostic Value of Pretreatment HER2 Status in Gastric Cancer Patients Treated with Postoperative Chemoradiotherapy
TURKISH JOURNAL of ONCOLOGY ORIGINAL ARTICLE Prognostic Value of Pretreatment HER2 Status in Gastric Cancer Patients Treated with Postoperative Chemoradiotherapy Ozan Cem GÜLER, 1 Mustafa KANDAZ, 1 Zümrüt
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationUpdate on Published CAP/ASCP/ASCOHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma
8001-17 Update on Published CAP/ASCP/ASCOHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma Kay Washington, MD, PhD Vanderbilt University Medical Center DISCLOSURE In the past
More informationCirculating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego
National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty
More informationNovel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,
More informationMeasure Specifications Measure Description
CMS ID/CMS QCDR ID: CAP 15 Title: BRAF Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Metastatic Colorectal Adenocarcinoma Specifications Description Denominator
More informationPrimary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings
CASE REPORT Primary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings Makoto Nagashima 1, Ayako Moriyama 1, Yasuo
More information위장관종양의표적치료를위한 면역조직화학적및분자병리학적 진단기법 이혜승 분당서울대학교병원병리과
위장관종양의표적치료를위한 면역조직화학적및분자병리학적 진단기법 이혜승 분당서울대학교병원병리과 Contents HER2 testing in gastric cancer - Clinicopathologic significance of HER2 - Practical approach of HER2 testing Resistance to anti-egfr therapy
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationMedical Policy. Description/Scope. Position Statement
L Subject: Document #: Current Effective Date: 01/05/2016 Status: Revised Last Review Date: 11/05/2015 Description/Scope This document addresses the indications for trastuzumab (Herceptin, Genentech, Inc.,
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationRESEARCH COMMUNICATION. Effect of HER-2/neu Over-expression on Prognosis in Gastric Cancer: A Meta-analysis
RESEARCH COMMUNICATION Effect of HER-2/neu Over-expression on Prognosis in Gastric Cancer: A Meta-analysis Shuyi Wang &, Gang Zheng &, Liangdong Chen, Bin Xiong* Abstract Background: Her-2/neu is the most
More informationSalivary duct carcinoma: A clinopathological report of 11 cases
ONCOLOGY LETTERS 10: 337-341, 2015 Salivary duct carcinoma: A clinopathological report of 11 cases XIAOFENG HUANG 1, JING HAO 2, SHENG CHEN 1 and RUNZHI DENG 3 1 Department of Pathology, 2 Central Laboratory,
More informationKey Words. Gastric cancer HER-2 Prognosis IHC FISH
The Oncologist Gastrointestinal Cancer Impact of HER-2 Overexpression/Amplification on the Prognosis of Gastric Cancer Patients Undergoing Resection: A Single-Center Study of 1,036 Patients JUN-TE HSU,
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationOptimal algorithm for HER2 testing
Optimal algorithm for HER2 testing The revised definition of IHC 2+ (equivocal) is invasive breast cancer with Weak to moderate complete membrane staining observed in >10% of tumor cells. (see Figure 1
More informationHER2/neu Evaluation of Breast Cancer in 2019
HER2/neu Evaluation of Breast Cancer in 2019 A.A. Sahin, M.D. Professor of Pathology and Translation Molecular Pathology Section Chief of Breast Pathology ERBB2 (HER2) Background 185-kDa membrane protein
More informationUpdate on Colorectal Cancer: Integrating the Host Immune Response 3 rd Emirates Surgical Pathology Conference 15 December 2017 Dubai, UAE
Update on Colorectal Cancer: Integrating the Host Immune Response 3 rd Emirates Surgical Pathology Conference 15 December 2017 Dubai, UAE Martine McManus, MD, FCAP Pathology & Laboratory Medicine Institute
More informationJournal of Breast Cancer
ORIGINAL ARTICLE Journal of Breast Cancer J Breast Cancer 2009 December; 12(4): 235-40 DOI: 10.4048/jbc.2009.12.4.235 Comparison of Silver-Enhanced in situ Hybridization and Fluorescence in situ Hybridization
More informationLow-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
Med Oncol (2014) 31:870 DOI 10.1007/s12032-014-0870-2 ORIGINAL PAPER Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer Jasmine Miger Annika Holmqvist Xiao-Feng Sun Maria Albertsson
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationHER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma
DISCOVERIES 2018, 6(4): e83 DOI: 10.15190/d.2018.6 EXPERIMENTAL Article HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma Nisha Raj 1, Divya Verma 1, Ashok Kumar 2,
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationDoes HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
MYERS et al. ORIGINAL ARTICLE Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey J.A. Myers MD FRCPC, G.
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationResearch Article HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder
Disease Markers Volume 2016, Article ID 8463731, 6 pages http://dx.doi.org/10.1155/2016/8463731 Research Article HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma
More informationClonal evolution of human cancers
Clonal evolution of human cancers -Pathology-based microdissection and genetic analysis precisely demonstrates molecular evolution of neoplastic clones- Hiroaki Fujii, MD Ageo Medical Laboratories, Yashio
More information